Exploring the Resistance Mechanism of Osimertinib and Monitoring the Treatment Response Using Plasma ctDNA in Chinese NSCLC Patients

被引：9
|
作者：
Shi, Y. [1 ,2 ]
Xing, P. [1 ,2 ]
Han, X. [3 ,4 ]
Wang, S. [5 ]
Liu, Y. [1 ,2 ]
Liu, P. [1 ,2 ]
Li, J. [1 ,2 ]
Chang, L. [5 ]
Guan, Y. [5 ]
Zhang, Z. [1 ,2 ]
Wu, D. [1 ,2 ]
Yao, J. [1 ,2 ]
Xin, Y. [5 ]
机构：
[1] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Med Oncol, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Dept Clin Lab, Beijing, Peoples R China
[4] Peking Union Med Coll, Beijing 100021, Peoples R China
[5] Geneplus Beijing Inst, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
plasma ctDNA; non-small cell lung cancer; Resistance;
D O I：
10.1016/j.jtho.2018.08.875
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.13-18
引用
收藏
页码：S589 / S589
页数：1
相关论文
共 50 条
  • [11] Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
    Watanabe, Kana
    Saito, Ryota
    Miyauchi, Eisaku
    Nagashima, Hiromi
    Nakamura, Atsushi
    Sugawara, Shunichi
    Tanaka, Nobuyuki
    Terasaki, Hiroshi
    Fukuhara, Tatsuro
    Maemondo, Makoto
    CANCERS, 2023, 15 (17)
  • [12] From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC
    Bordi, Paola
    Del Re, Marzia
    Minari, Roberta
    Rofi, Eleonora
    Buti, Sebastiano
    Restante, Giuliana
    Squadrilli, Anna
    Crucitta, Stefania
    Casartelli, Chiara
    Gnetti, Letizia
    Azzoni, Cinzia
    Bottarelli, Lorena
    Petrini, Iacopo
    Cosenza, Agnese
    Ferri, Leonarda
    Rapacchi, Elena
    Danesi, Romano
    Tiseo, Marcello
    LUNG CANCER, 2019, 131 : 78 - 85
  • [13] ctDNA in treatment response monitoring in patients with relapsed gynecologic malignancies.
    Williams, Jason Russell
    Grzankowski, Kassondra
    Castaneda, Kayla
    Saldivar, Jose Salvador
    Diaz-Arrastia, Concepcion
    Azzi, Georges
    Sindhu, Hemant
    Chae, Young Kwang
    Kalashnikova, Ekaterina
    Nicosia, Brittany
    Tekula, Shilpa
    George, Giby V.
    Malhotra, Meenakshi
    ElNaggar, Adam
    Aleshin, Alexey
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17501 - E17501
  • [14] Serial Plasma ctDNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in T790M+NSCLC
    Liao, B.
    Hsu, W.
    Lee, J.
    Yang, C.
    Tsai, T.
    Liao, W.
    Ho, C.
    Lin, C.
    Shih, J.
    Yu, C.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S654 - S654
  • [15] Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib
    Ishii, Hidenobu
    Azuma, Koichi
    Sakai, Kazuko
    Naito, Yoshiko
    Matsuo, Norikazu
    Tokito, Takaaki
    Yamada, Kazuhiko
    Hoshino, Tomoaki
    Nishio, Kazuto
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [16] Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib
    Hidenobu Ishii
    Koichi Azuma
    Kazuko Sakai
    Yoshiko Naito
    Norikazu Matsuo
    Takaaki Tokito
    Kazuhiko Yamada
    Tomoaki Hoshino
    Kazuto Nishio
    Scientific Reports, 10
  • [17] Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial.
    Hu, Min
    Wu, Yi-Long
    Zhu, Xuehua
    Sun, Yun
    Lu, Xuesong
    Wang, Jia
    Wang, Mengzhao
    Cheng, Ying
    Chen, Yuan
    Zhao, Yanqiu
    Shi, Yuankai
    Lu, You
    Shi, Meiqi
    Zhang, Helong
    Huang, Xiangning
    Ding, Zhijie
    Chen, George
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [18] Effect of longitudinal ctDNA monitoring with resistance genomic signatures on prognostication in patients with EGFR-mutated advanced NSCLC
    Prabhash, Kumar
    Bharde, Atul
    Behel, Vichitra
    Ratnaparkhi, Mrunal
    Noronha, Vanita
    Patil, Vijay Maruti
    Choughule, Anuradha
    Chandrani, Pratik
    Dutt, Amit
    Jadhav, Bhagwat
    Prajapati, Sangeeta
    Haldar, Sumit
    Mobeen, Fauzul
    Menon, Nandini Sharrel
    Hariramani, Kanchan
    Basavalingegowda, Madhura
    Chaturvedi, Pankaj
    Khandare, Jayant
    Shafi, Gowhar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [19] Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment
    Ntzifa, Aliki
    Marras, Theodoros
    Kallergi, Galatea
    Kotsakis, Athanasios
    Georgoulias, Vasilis
    Lianidou, Evi
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [20] Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy
    Falk, Markus
    Willing, Eva
    Schmidt, Stefanie
    Schatz, Stefanie
    Galster, Marco
    Tiemann, Markus
    Ficker, Joachim H.
    Brueckl, Wolfgang M.
    CURRENT ONCOLOGY, 2023, 30 (02) : 1692 - 1698
12345